Catherine J. Mackey - Aug 15, 2022 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Role: Director
Signature: /s/ Robert Hesslein, as Attorney-in-Fact for Catherine J. Mackey
Stock symbol: VYGR
Transactions as of: Aug 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 8/16/2022, 05:03 PM
Previous filing: Apr 6, 2022
Next filing: Dec 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VYGR	Stock Option (Right to Buy)	Award	$0	+44K		$0.00	44K	Aug 15, 2022	Common Stock	44K	$6.02	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/16th of the shares of common stock underlying the option vesting upon the three-month anniversary of the Vesting Commencement Date and an additional 1/16th of the shares of common stock underlying the option vesting at the end of each successive three-month period thereafter, subject to the Reporting Person's continued service as a director.

Content

This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over four years, with 1/16th of the shares of common stock underlying the option vesting upon the three-month anniversary of the Vesting Commencement Date and an additional 1/16th of the shares of common stock underlying the option vesting at the end of each successive three-month period thereafter, subject to the Reporting Person's continued service as a director.